消癌平片联合SOX方案治疗胃癌的临床研究

Clinical study on Xiao'aiping Tablets combined with SOX chemotherapy in treatment of gastric cancer

目的探讨消癌平片联合SOX方案治疗胃癌的临床疗效。方法选取2013年1月—2017年5月洛阳市第六人民医院收治的胃癌术后化疗患者300例为研究对象,根据随机数字表法将所有患者随机分为对照组和治疗组,每组各150例。对照组采用SOX方案辅助化疗,即第1天静脉滴注注射用奥沙利铂,130 mg/m2加入到5%葡萄糖注射液500 m L中,滴注2 h以上,1次/3周;并口服替吉奥胶囊,2～3粒/次,2次/d,连续治疗14 d,停药7 d,3周为1个周期。治疗组在对照组治疗的基础上口服消癌平片,6～8片/次,3次/d,连续治疗14 d,停药7 d,3周为1个周期。两组患者均连续治疗4个周期。观察两组的临床疗效,比较两组的视觉模拟评分法(VAS)评分、生命质量测定量表(QLQ-C30)评分、T细胞亚群和不良反应。结果治疗后,对照组和治疗组的总有效率、疾病控制率分别为44.00%、56.67%,74.67%、88.67%,两组比较差异有统计学意义(P<0.05)。治疗后,两组VAS评分显著降低,QLQ-C30评分显著升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些指标明显优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组CD3+、CD4+、CD4+/CD8+均显著升高,CD8+水平显著降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组T细胞亚群指标明显优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组Ⅲ度和Ⅳ度骨髓抑制、恶心呕吐、便秘腹泻、肝肾功能损害发生率显著低于对照组,两组比较差异有统计学意义(P<0.05)。结论消癌平片联合SOX方案治疗胃癌具有较好的临床疗效,能减轻疼痛,提高免疫功能,改善生活质量,安全性高,具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Xiao＇aiping Tablets combined with SOX chemotherapy in treatment of gastric cancer. Methods Patients（300 cases） with gastric cancer of postoperative chemotherapy in the Sixth People＇s Hospital of Luoyang from January 2013 to May 2017 were randomly divided into control and treatment groups, and each group had 150 cases. Patients in the control group were given SOX chemotherapy. At first day, patients were iv administered with Oxaliplatin for injection, 130 mg/m2 added into 5% glucose solution 500 mL, dropped for 2 h, once every 3 weeks. And Patients in the control group were po administered with Tegafur, Gimeracil and Oteracil Potassium Capsules, 2 — 3 grains/time, twice daily, treated for 14 d, then stopped for 7 d, 3 weeks for a course. Patients in the treatment group were po administered with Xiao＇aiping Tablets on the basis of the control group, 6 — 8 tablets/time, three times daily, treated for 14 d, then stopped for 7 d, 3 weeks for a course. Patients in two groups were treated for 3 courses. After treatment, the clinical efficacies were evaluated, and VAS scores, QLQ-C30 scores, T cell subsets, and adverse reactions in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 44.00% and 56.67%, respectively, and the disease control rates in the control and treatment groups were 74.67% and 88.67%, respectively, and there was difference between two groups（P〈0.05）. After treatment, VAS scores in two groups were significantly decreased, but QLQ-C30 scores in two groups were significantly increased, and the difference was statistically significant in the same group（P〈0.05）. And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups（P〈0.05）. After treatment, the levels of CD3＋、CD4＋、CD4＋/CD8＋ in two groups were significantly increased, but the levels of CD8＋ in two groups were significantly decreased, and the difference was statistically significant in the same group（P〈0.05）. And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups（P〈0.05）. After treatment, the degree III and IV incidence rate of bone marrow suppression, nausea and vomiting, constipation, diarrhea, liver and kidney damage in the treatment group were significantly lower than those in the control group, and there was difference between two groups（P〈0.05）. Conclusion Xiao＇aiping Tablets combined with SOX chemotherapy has clinical curative effect in treatment of gastric cancer, can relieve pain, enhance immune function, and improve the quality of life, with good safety, which has a certain clinical application value.